Pulmonary damage in a patient with hairy cell leukemia - infectious involvement or hematological disease activity? Case report
Jazyk angličtina Země Česko Médium print-electronic
Typ dokumentu kazuistiky, časopisecké články
PubMed
35713332
DOI
10.5507/bp.2022.026
Knihovny.cz E-zdroje
- Klíčová slova
- cladribine, hairy cell leukemia, interferon-alfa, pulmonary infiltration,
- MeSH
- kladribin terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- plíce MeSH
- protinádorové látky * terapeutické užití MeSH
- vlasatobuněčná leukemie * komplikace diagnóza farmakoterapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
- Názvy látek
- kladribin MeSH
- protinádorové látky * MeSH
BACKGROUND: Hairy cell leukemia (HCL) is a rare indolent lymphoproliferative disease with an accumulation of mature B lymphocytes with fine reticular chromatin and cytoplasm with typical hairy-like cytoplasmic projections. Rarely, hairy cell leukemia manifests as a lung infiltration. The differential diagnosis between infection and malignant involvement with hairy cell leukemia is often challenging in such situations. METHODS AND RESULTS: We present a 53-year-old female with an uncommon pulmonary involvement with hairy cell leukemia. In addition, we discuss the complicated differential diagnosis of pulmonary disease in patients with hairy cell leukemia and the treatment approach to these patients. CONCLUSION: This case report describes the successful therapy management of a patient with pulmonary involvement by hairy cell leukemia. Therapy with interferon-alfa and cladribine resulted in long-term remission of the underlying disease.
Department of Clinical Pharmacy Hospital Pharmacy University Hospital Hradec Kralove Czech Republic
Department of Radiology University Hospital Hradec Kralove Czech Republic
The Fingerland Department of Pathology University Hospital Hradec Kralove Czech Republic
Zobrazit více v PubMed
Staines A, Cartwright RA. Hairy cell leukaemia: descriptive epidemiology and a case-control study. Br J Haematol 1993;85(4):714-7. DOI
Troussard X, Cornet E. Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment. Am J Hematol 2017;92(12):1382-90. DOI
Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 2017;129(5):553-60. DOI
Uzunhan Y, Cadranel J, Boissel N, Gardin C, Arnulf B, Bergeron A. Lung involvement in lymphoid and lympho-plasmocytic proliferations (except lymphomas). Rev Mal Respir 2010;27(6):599-610. DOI
Vardiman JW, Golomb HM. Autopsy findings in hairy cell leukemia. Semin Oncol 1984;11(4):370-80.
Hansen T, Constantin C, Weber M, Titze U, Hartmann F. Bronchoalveolar lavage in hairy cell leukemia with pulmonary infiltration. Pathologe 2019;40(5):529-33. DOI
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 52-1982. A 50-year-old man with hairy-cell leukemia, recurrent fever, and variable pulmonary infiltrates. N Engl J Med 1982;307(27):1693-700.
Falini B, Tiacci E. New treatment options in hairy cell leukemia with focus on BRAF inhibitors. Hematol Oncol 2019;37(S1):30-7. DOI
Saven A, Piro LD. Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2'-deoxycoformycin. Ann Intern Med 1993;119(4):278-83. DOI
Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci 2005;27(6):423-31. DOI
Golomb HM, Jacobs A, Fefer A, Ozer H, Thompson J, Portlock C, Ratain M, Golde D, Vardiman J, Burke JS. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. J Clin Oncol 1986;4(6):900-5. DOI
Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D. Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017;15(11):1414-27. doi: 10.6004/jnccn.2017.0165 PubMed DOI
Park JH, Winer ES, Huntington SF, von Keudell G, Vemuri S, Shukla M, et al. First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl. Blood 2021;138(Supplement 1):43. DOI
Thomas DA, O'Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, Cortes J, Kantarjian HM. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102(12):3906-11. DOI
Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia 2018;32(8):1768-77. DOI
Tiacci E, De Carolis L, Simonetti E, Capponi M, Ambrosetti A, Lucia E, Antolino A, Pulsoni A, Ferrari S, Zinzani PL, Ascani S, Perriello VM, Rigacci L, Gaidano G, Della Seta R, Frattarelli N, Falcucci P, Foà R, Visani G, Zaja F, Falini B. Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. N Engl J Med 2021;384(19):1810-23. DOI
